Aurobindo Pharma Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Kunal Singla
- Category: Market
Aurobindo Pharma share price Rs 1,676.20 (9 October 2026). Base target Rs 1,733, bull Rs 2,106, downside risk Rs 1,314. PE 25.46. 52W range Rs 1,066.80 to Rs 1,740.00.
Quick Answer
The Aurobindo Pharma share price target for 2027 is Rs 1,733, about 3.4% above the current price of Rs 1,676.20. The bull case is Rs 2,106, and the downside risk level, which is not a target, is Rs 1,314. The base case assumes earnings per share grow 5.6% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 25.46. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing an Aurobindo Pharma target price for 2027 should start with where the stock sits today. At Rs 1,676.20 on 9 October 2026, it is 3.7% below its 52-week high of Rs 1,740.00 and 57.1% above its 52-week low of Rs 1,066.80. That range spans 63% from low to high, so the entry point matters as much as the Aurobindo Pharma price forecast itself.
This article builds the Aurobindo Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 1,733 base case and the Rs 2,106 bull case were reached, along with a downside risk level of Rs 1,314.
Click Here – Get Free Investment Predictions
Aurobindo Pharma Stock Analysis: Company Overview and Key Stats
Aurobindo Pharma (NSE: AUROPHARMA) has a market capitalisation of Rs 94,477 crore. In FY26 it reported revenue of Rs 34,145 crore and net profit of Rs 3,503 crore. The table collects the figures the Aurobindo Pharma share price target is built on.
| Metric | Value |
|---|---|
| Company | Aurobindo Pharma |
| NSE Ticker | AUROPHARMA |
| CMP (9 October 2026) | Rs 1,676.20 |
| 52-Week High | Rs 1,740.00 |
| 52-Week Low | Rs 1,066.80 |
| Market Cap | Rs 94,477 crore |
| PE Ratio (TTM) | 25.46 |
| Industry PE | 37.59 |
| Price to Book | 2.49 |
| Return on Equity | 9.25% |
| Debt to Equity | 0.21 |
| EPS (TTM) | Rs 64.49 |
| Dividend Yield | 0.25% |
| 12-Month Base Target | Rs 1,733 |
| Bull Case | Rs 2,106 |
| Downside Risk Level (not a target) | Rs 1,314 |
Why Is Aurobindo Pharma Share Price Target Set at Rs 1,733 for 2027?
The base-case Aurobindo Pharma stock target of Rs 1,733 applies a PE multiple of 25.46 to a forward EPS estimate of Rs 68.07. That EPS assumes 5.6% yearly growth, the pace from FY24 to FY26, and puts the target 3.4% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Aurobindo Pharma Target Price: Five Years of Results
Aurobindo Pharma grew revenue from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew more slowly, from Rs 2,647 crore to Rs 3,503 crore (7.3% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 23,775.84 | 2,647.11 | 45.20 | 9.00 |
| FY23 | 25,145.97 | 1,927.65 | 32.90 | 7.50 |
| FY24 | 29,559.25 | 3,168.97 | 54.16 | 4.50 |
| FY25 | 32,345.58 | 3,483.57 | 59.81 | 0.00 |
| FY26 | 34,145.17 | 3,502.97 | 60.34 | 4.00 |
FY26 revenue growth was 5.6%, slower than the four-year average of 9.5%, and net profit moved up 0.6%. EPS rose from Rs 54.16 in FY24 to Rs 60.34 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Aurobindo Pharma converted 10.3% of FY26 revenue into net profit, against 10.8% in FY25, within a five-year range of 7.7% to 11.1%. EBITDA margin was 21.3% in FY26 versus 22.2% in FY25.
In the June 2026 quarter, revenue was Rs 9,415 crore, up 18.1% from the same quarter a year earlier, while net profit of Rs 1,032 crore was up 25.2%. EBITDA came in at Rs 2,145 crore, up 25.6% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.21, and shareholders’ equity grew from Rs 24,574 crore in FY22 to Rs 37,883 crore in FY26. Operating cash flow in FY26 was Rs 5,526 crore against capital expenditure of Rs 3,105 crore, leaving free cash flow of Rs 2,422 crore, or 2.6% of the current market capitalisation. In FY25 free cash flow was Rs 1,405 crore.
Valuation Check for the Aurobindo Pharma Stock Target: PE, Price to Book and ROE
At a PE of 25.46 against an industry PE of 37.59, Aurobindo Pharma trades at a discount to its industry. Price to book is 2.49 on a book value of Rs 658.53 per share, and return on equity is 9.25%. A PE of 25.46 equals an earnings yield of 3.9%, and the FY26 dividend of Rs 4.00 per share gives a yield of 0.25%.
Shareholding Pattern and Institutional Holding
Promoters held 51.88% of Aurobindo Pharma in June 2026, and promoter holding has stayed near 51.88% since June 2025. Foreign institutional investors (FII) held 16.38% and domestic institutions (DII) held 25.10%, which puts total institutional holding at 41.48%. FII holding rose from 14.37% in June 2025 to 16.38% in June 2026. Public shareholders own the remaining 6.64%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Aurobindo Pharma Share Price Targets for the Short Term and 12 Months
Short Term Aurobindo Pharma Stock Target Levels: Technical Setup
At Rs 1,676.20 on 9 October 2026, Aurobindo Pharma trades above its 50-day simple moving average of Rs 1,656.31 and above its 200-day exponential moving average of Rs 1,475.31. The 14-day RSI reads 36.1, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,740.00 (52-week high) and the nearest support is Rs 1,656.31 (50-day simple moving average). A sustained move above Rs 1,740.00 would improve the short-term setup, while a close below Rs 1,656.31 would shift attention to the next support.
12 Month Aurobindo Pharma Target Price for 2027
The 12-month target for Aurobindo Pharma is Rs 1,733: forward EPS of Rs 68.07 at a PE of 25.46. That is 3.4% above Rs 1,676.20. It would still leave the stock 0.4% below its 52-week high of Rs 1,740.00. The upside in the base case is thin, so the thesis here leans on the bull case and on patience.
How EPS Growth and PE Multiple Change the Aurobindo Pharma Target Price
| EPS Growth | PE 20.37 | PE 25.46 | PE 29.28 |
|---|---|---|---|
| 0.0% (EPS Rs 64.49) | Rs 1,314 | Rs 1,642 | Rs 1,888 |
| 5.6% (EPS Rs 68.07) | Rs 1,387 | Rs 1,733 | Rs 1,993 |
| 11.6% (EPS Rs 71.94) | Rs 1,465 | Rs 1,832 | Rs 2,106 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Aurobindo Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Aurobindo Pharma Stock Target in 2027
Bull Case Rs 2,106
The bull case Aurobindo Pharma price target needs EPS growth of 11.6%, which lifts forward EPS to Rs 71.94, and a PE multiple that rises 15% to 29.28. That gives Rs 2,106, 25.6% above the current price and above the 52-week high of Rs 1,740.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,314
The downside risk level is not a target. It assumes EPS stays flat at Rs 64.49 and the PE falls 20% to 20.37. That gives Rs 1,314, 21.6% below the current price and above the 52-week low of Rs 1,066.80.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 11.6% | 29.28 | Rs 2,106 | +25.6% |
| Base Case | 5.6% | 25.46 | Rs 1,733 | +3.4% |
| Downside Risk | 0.0% | 20.37 | Rs 1,314 | -21.6% |
Key Risks to the Aurobindo Pharma Target Price for 2027
Growth Slowdown Risk for the Aurobindo Pharma Price Target
Revenue in the June 2026 quarter was up 18.1% year on year, and FY26 revenue growth was 5.6%. If growth slows from here, the EPS estimate behind the Aurobindo Pharma stock target will need revising.
Liquidity and Size Risk
Aurobindo Pharma has a market capitalisation of Rs 94,477 crore. Institutional holding is 41.48%, and promoters hold 51.88%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.
Valuation and Margin Risk
Net margin was 10.3% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 25.46 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 20.37 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 3.7% below its 52-week high, with an RSI of 36.1 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in Aurobindo Pharma
Start with the live price and volume. Any Aurobindo Pharma share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 1,676.20 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Aurobindo Pharma’s PE, ROE, debt and shareholding in one place.
Check Aurobindo Pharma fundamentals on the Univest Screener
Then compare the three Aurobindo Pharma target price scenarios with your own view. If you expect EPS growth below 5.6%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma live price and get daily stock recommendations.
Conclusion
The Aurobindo Pharma share price target for 2027 is Rs 1,733 in the base case, with Rs 2,106 as the bull case. The support for that view is arithmetic you can check: EPS grew 5.6% a year over FY24 to FY26, and the stock trades at a PE of 25.46. The risks are equally concrete, including a stock that sits 3.7% below its 52-week high and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Aurobindo Pharma Share Price Target 2027
What is the Aurobindo Pharma share price target for 2027?
Ans. The base-case Aurobindo Pharma share price target for 2027 is Rs 1,733, with Rs 2,106 as the bull case. The downside risk level, which is not a target, is Rs 1,314. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the Aurobindo Pharma share price today?
Ans. As of 9 October 2026, 12:52 PM IST, Aurobindo Pharma trades at Rs 1,676.20, up 1.90% on the day. The 52-week range is Rs 1,066.80 to Rs 1,740.00.
Is Aurobindo Pharma a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 5.6% a year over FY24 to FY26, but the stock is 3.7% below its 52-week high. Whether Aurobindo Pharma fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for Aurobindo Pharma shares?
Ans. The bull case target is Rs 2,106, which assumes 11.6% EPS growth and a PE of 29.28. The downside risk level is Rs 1,314, which assumes flat EPS and a PE of 20.37. It marks a risk, not a target.
What are the main risks to the Aurobindo Pharma price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 94,477 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of Aurobindo Pharma and how does it compare with the industry?
Ans. The PE ratio of Aurobindo Pharma is 25.46 against an industry PE of 37.59. Price to book is 2.49 and return on equity is 9.25%. The base case in the Aurobindo Pharma price target holds this PE constant.
Who owns Aurobindo Pharma, and what is the promoter holding?
Ans. Promoters held 51.88% of Aurobindo Pharma in June 2026. FII held 16.38%, DII held 25.10% and the public held 6.64%.
What were Aurobindo Pharma’s latest quarterly results?
Ans. In the June 2026 quarter, Aurobindo Pharma reported revenue of Rs 9,415 crore (up 18.1% year on year) and net profit of Rs 1,032 crore (up 25.2%).
